Zewen Wei

Dr. Zewen Wei


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2019 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
RLRen Li
Ren Li
FJFei Jia
Fei Jia
WZWeikai Zhang
Weikai Zhang
FSFanghao Shi
Fanghao Shi
ZFZhiguo Fang
Zhiguo Fang
ZWZewen Wei
Zewen Wei
To sequence single circulating tumor cells (CTCs) from whole blood, a microfluidic chip was developed to perform blood filtering/CTC enrichment/CTC sorting and in situ MDA for whole genome sequencing.

YCYuqing Chang
Yuqing Chang
YWYuqian Wang
Yuqian Wang
WLWen Li
Wen Li
ZWZewen Wei
Zewen Wei
STShichuan Tang
Shichuan Tang
Rui ChenRui Chen
Rui Chen
Airborne viruses, such as COVID-19, cause pandemics all over the world. Virus-containing particles produced by infected individuals are suspended in the air for extended periods, actually resulting in viral aerosols and the spread of infectious diseases. Aerosol collection and detection devices are essential for limiting the spread of airborne virus diseases. This review provides an overview of the primary mechanisms and enhancement techniques for collecting and detecting airborne viruses. Indoor virus detection strategies for scenarios with varying ventilations are also summarized based on the excellent performance of existing advanced comprehensive devices. This review provides guidance for the development of future aerosol detection devices and aids in the control of airborne transmission diseases, such as COVID-19, influenza and other airborne transmission viruses.

4 June 2024 in Analytical Chemistry
Verified
Journal Article
Closed access
KZKexin Zhang
Kexin Zhang
JXJiyu Xi
Jiyu Xi
YWYadong Wang
Yadong Wang
JXJianchao Xue
Jianchao Xue
BLBowen Li
Bowen Li
ZWZewen Wei
Zewen Wei

24 August 2022 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
HZHuiting Zhao
Huiting Zhao
XWXu Wang
Xu Wang
ZGZhanhui Geng
Zhanhui Geng
NLNaixin Liang
Naixin Liang
QLQin Li
Qin Li
ZWZewen Wei
Zewen Wei
Photodynamic therapy (PDT), as a globally accepted method for treating different forms of skin or mucosal disorders, requires efficient co-delivery of photosensitizers and corresponding therapeutic light. The adverse effects of intravenous injection of photosensitizers have been reduced by the development of microneedle arrays for transdermal local photosensitizer delivery. However, the drawbacks of the only available therapeutic light delivery method at the moment, which is directly applying light to the skin surface, are yet to be improved. This study presents a new strategy in which therapeutic light and photosensitizer were transdermally co-delivered into local tissues. A flexible dual-function microneedle array (DfMNA) which contains 400 microneedles was developed. Each microneedle consists of a dissolvable needle tip (140 μm in height) for delivering the photosensitizer and a transparent needle body (660 μm in height) for guiding therapeutic light. Using port-wine stains, which is a frequently occurring skin disorder caused by vascular malformation, as a model disease, the effectiveness of DfMNA mediated PDT has been verified on mice. Compared with the standard operation procedure of clinical PDT, the DfMNA decreases the amount of photosensitizer from 300 μg to 0.5 μg and reduces therapeutic light irradiance from 100 mW cm−2 to 60 mW cm−2 while realizing better treatment effects. As a result, the skin damage and the burden on the metabolic system have been alleviated. The DfMNA has a remarkably reduced photosensitizer amount and, for the first time, realized transdermal delivery of therapeutic light for PDT, thus avoiding the disadvantages of existing PDT methodologies.

14 February 2024 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
KZKexin Zhang
Kexin Zhang
JXJiyu Xi
Jiyu Xi
HZHuiting Zhao
Huiting Zhao
YWYadong Wang
Yadong Wang
JXJianchao Xue
Jianchao Xue
ZWZewen Wei
Zewen Wei
Many efforts have been paid to advance the effectiveness of personalized medicine for lung cancer patients. Sequencing-based molecular diagnosis of EGFR mutations has been widely used to guide the selection of anti-lung-cancer drugs. Organoid-based assays have also been developed to ex vivo test individual responses to anti-lung-cancer drugs. After addressing several technical difficulties, a new combined strategy, in which anti-cancer medicines are first selected based on molecular diagnosis and then ex vivo tested on organoids, has been realized in a single dual-functional microfluidic chip. A DNA-based nanoruler has been developed to detect the existence of EGFR mutations and shrink the detection period from weeks to hours, compared with sequencing. The employment of the DNA-based nanoruler creates a possibility to purposively test anti-cancer drugs, either EGFR-TKIs or chemotherapy drugs, not both, on limited amounts of organoids. Moreover, a DNA-based nanosensor has been developed to recognize intracellular ATP variation without harming cell viability, realizing in situ monitoring of the whole course growth status of organoids for on-chip drug response test. The dual-functional microfluidic chip was validated by both cell lines and clinical samples from lung cancer patients. Furthermore, based on the dual-functional microfluidic chip, a fully automated system has been developed to span the divide between experimental procedures and therapeutic approaches. This study constitutes a novel way of combining EGFR mutation detection and organoid-based drug response test on an individual patient for guiding personalized lung cancer medicine.

2 August 2024 in Analytical Chemistry
Verified
Journal Article
Closed access
MGMingyao Gao
Mingyao Gao
WDWenyong Ding
Wenyong Ding
YWYadong Wang
Yadong Wang
BLBowen Li
Bowen Li
ZHZhicheng Huang
Zhicheng Huang
ZWZewen Wei
Zewen Wei